Evidence map›Paper›PMID 42469871›Full record

ArticleJournal of translational medicine2026

TRIM24 stabilizes the p110 CUX1 oncoprotein via USP10 to promote chemoresistance in acute myeloid leukemia.

Zhi-Yin Ke, Jie Li, Liang Zhong, Shan Chen, Li-Ran Liu, Ting Xu, Bei-Zhong Liu, Li-Hua Yu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zhi-Yin Ke *Clinical Laboratory, The Affiliated Yongchuan Hospital of Chongqing Medical University, Chongqing, 402160, China.
Jie Li *Clinical Laboratory, The Affiliated Yongchuan Hospital of Chongqing Medical University, Chongqing, 402160, China.
Liang ZhongKey Laboratory of Laboratory Medical Diagnostics, Ministry of Education, Department of Laboratory Medicine, Chongqing Medical University, Chongqing, 400016, China.
Shan ChenClinical Laboratory, The Affiliated Yongchuan Hospital of Chongqing Medical University, Chongqing, 402160, China.
Li-Ran LiuClinical Laboratory, The Affiliated Yongchuan Hospital of Chongqing Medical University, Chongqing, 402160, China.
Ting XuClinical Laboratory, The Affiliated Yongchuan Hospital of Chongqing Medical University, Chongqing, 402160, China.
Bei-Zhong LiuClinical Laboratory, The Affiliated Yongchuan Hospital of Chongqing Medical University, Chongqing, 402160, China. liubeizhong@cqmu.edu.cn.
Li-Hua YuClinical Laboratory, The Affiliated Yongchuan Hospital of Chongqing Medical University, Chongqing, 402160, China. YLH@hospital.cqmu.edu.cn.

Funding

Chongqing Natural Science Foundation Project CSTB2023NSCQ-MSX0222Chongqing public health key specialty (discipline) project Chongqing public health key specialty (discipline) projectMedical Research Project of Chongqing Municipal Science and Technology Commission and Health Commission 2026MSXM004Scientific Research Project of Yongchuan Hospital Affiliated to Chongqing Medical University YJJL2024070Scientific Research Project of Yongchuan Hospital Affiliated to Chongqing Medical University YJJL2024073
6 · The paper itself

Abstract

backgroundAcute myeloid leukemia (AML) has a poor prognosis due to high chemoresistance and recurrence. TRIM24, an E3 ubiquitin ligase, is oncogenic in solid tumors, but its role in AML and regulation of the oncoprotein p110 CUX1 remain unclear.

methodsWe performed bioinformatic analysis to assess TRIM24 expression, prognosis, and protein-protein interactions. Functional studies used genetic manipulation and pharmacological inhibition in AML cells. Protein interactions were examined by Co-IP, IP-MS, and immunofluorescence. The stability and ubiquitination of p110 CUX1 were examined via CHX chase assays and ubiquitination profiling. The biological and therapeutic significance of the identified axis was validated using cell proliferation, apoptosis assays, drug sensitivity tests, and a CDX mouse model.

resultsTRIM24 is overexpressed in AML and predicts poor prognosis. TRIM24 promotes proliferation and inhibits apoptosis. Mechanistically, TRIM24 functions as a scaffold-like adaptor to recruit USP10 to deubiquitinate and stabilize p110 CUX1 via K48-linked ubiquitin chain cleavage. The TRIM24/USP10/p110 CUX1 axis activates the MAPK signaling pathway, with CUX1 regulating ERK transcription. TRIM24 overexpression enriches DNA repair pathways, conferring cytarabine resistance. Targeting TRIM24 genetically or with dTRIM24 sensitizes AML cells to cytarabine in vitro and in vivo.

conclusionOur study reveals a novel non-canonical role of TRIM24 as a stabilizer of the p110 CUX1 oncoprotein by recruiting USP10. This TRIM24/USP10/p110 CUX1 axis is critical for AML progression, clinical prognosis, and chemoresistance, presenting a promising therapeutic target for AML treatment.

Indexed as

Carrier ProteinsDrug Resistance, NeoplasmLeukemia, Myeloid, AcuteNuclear ProteinsRepressor ProteinsUbiquitin ThiolesteraseAnimalsApoptosisCell Line, TumorCell ProliferationHomeodomain ProteinsHumansMicePrognosisProtein BindingProtein StabilityCarrier ProteinsCUX1 protein, humanHomeodomain ProteinsNuclear ProteinsRepressor ProteinsTranscription FactorsTRIM24 protein, humanUbiquitin ThiolesteraseAcute myeloid leukemiaChemoresistancep110 CUX1TRIM24Ubiquitination

Identifiers

PMID42469871
PMCPMC13560220

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.